Chiasma, Inc. (CHMA)
CHMA Price and Sentiment
CHMA Latest news
Amryt Pharma PLC has completed its acquisition of US group Chiasma Inc with Raj Kannan and Roni Mamluk joining the board as non-executive directors. Joe Wiley, Amryt's chief executive, said: “This transaction further solidifies our position as a global leader in treating rare and orphan conditions.
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm2021-07-10 13:59
NEW YORK , July 10, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: 1Life Healthcare, Inc. (NASDAQ: ONEM) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Iora Health. Under the terms of the merger, 1Life Healthcare will acquire Iora Health in an all-stock transaction.
Chiasma Inc (NASDAQ: CHMA) submitted a marketing application to the European Medicines Agency seeking approval of Mycapssa (oral octreotide capsules) as maintenance therapy for adults with acromegaly. The application is supported by positive results from Phase 3 MPOWERED non-inferiority trial comparing Mycapssa to long-acting injectable somatostatin analogs (iSSAs).
Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency2021-06-28 16:12
Submission supported by previously announced data from Phase 3 MPOWERED™ study Submission supported by previously announced data from Phase 3 MPOWERED™ study
Chiasma Inc (NASDAQ: CHMA) has presented patient-reported outcomes (PROs) data from its MPOWERED Phase 3 trial of Mycapssa for acromegaly, a hormonal disorder in which the pituitary gland produces too much growth hormone. Data demonstrated that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to Mycapssa.
Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly2021-05-27 16:05
--Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- --Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®--
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences2021-05-20 08:00
-- New clinical data accepted for oral and e-Poster presentation at AACE -- -- e-ECE clinical data previously presented at Endocrine Society's 2021 annual meeting --
Acentrus Specialty Contracts with Chiasma to Bring MYCAPSSA® (octreotide) to Health Systems and Hospitals in the Acentrus Network2021-05-13 16:00
IRVING, Texas--(BUSINESS WIRE)--Acentrus Specialty™ has finalized an agreement with Chiasma, Inc. to provide qualified Acentrus clients access to MYCAPSSA® (octreotide).
Chiasma (CHMA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Amryt Pharma plc (AMYT) Amryt Pharma Acquisition of Chiasma Inc. and Q1 2021 Earnings Conference (Transcript)2021-05-08 20:01
Amryt Pharma plc (AMYT) Amryt Pharma Acquisition of Chiasma Inc. and Q1 2021 Earnings Conference (Transcript)